Albert SM, NEAD Study Group et al. Medication management skill in HIV: I. Evidence for adaptation of medication management strategies in people with cognitive impairment. II. Evidence for a pervasive lay model of medication efficacy. AIDS Behav 7(3): 329-338, 2003.
Baldewicz TT et al. Changes in neuropsychological functioning with progression of HIV-1 infection: results of an 8-year longitudinal investigation. AIDS Behav 8: 345-355, 2004.
Becker JT et al. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 18: S11-S18, 2004.
Belec L et al. Low prevalence of neuropsychiatric clinical manifestations in central African patients with acquire immune deficiency syndrome. Trans R Soc Trop Med Hyg 83:844-846, 1989.
Birbeck G et al. A study of HIV-dementia among hospice patients in Lusaka, Zambia. Presented at Assessment of NeuroAIDS in Africa, Blantyre, Malawi, 2004.
Birbeck GL. Barriers to care for patients with neurologic disease in rural Zambia. Archives of Neurology;57(3):414-417, 2000
Birbeck GL, Munsat T. Neurological services in sub-Saharan Africa: a case study among Zambian primary healthcare workers. Journal of Neurological Sciences 200(1-2): 75-78, 2002.
Brana C et al. A soluble factor produced by macrophages mediates the neurotoxic effects of HIV-1 tat in vitro. AIDS 13(12):1443-1452, 1999.
Brew BJ and González-Scarano F. HIV-associated dementia. An inconvenient truth. Neurology 68:324-325, 2007.
Cherner M et al. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS 18: S27-S34, 2004.
Clifford DB, Evans S. Ethiopian NeuroAIDS assessment. Presented at Assessment of NeuroAIDS in Africa, Tanzania, 2006.
Dore GJ et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13(10):1249-1253, 1999.
Dore GJ et al. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. Journal of Acquired Immune Deficiency Syndromes 29(4):388-395, 2002.
Elder GA, Server JL. AIDS and neurological disorders: an overview. Ann Neurol 23:s2-s6, 1998.
Gonzalez E et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A;99(21):13795-13800, 2002.
Hall C. HIV-Associated dementia in the HAART era. Presented at Assessment of NeuroAIDS in Africa, Tanzania, 2006.
Hall C. Human immunodeficiency virus infection: nervous system involvement. Presented at Assessment of NeuroAIDS in Africa, Blantyre, Malawi, 2004.
Howlett WP et al. Neurological disorders in AIDS and HIV disease in the northern zone of Tanzania. AIDS 3:289-296, 1989.
Ives NJ et al. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. Journal of Infectious Diseases 42(2):134-139, 2001.
Maj M et al. WHO neuropsychiatric AIDS study, cross-sectional phase II neuropsychological and neurological findings. Arch Gen Psyc 51(1):51-61, 1994.
Mayeya J et al. Zambia mental health country profile. International Review of Psychiatry 16(1–2), 63–72, 2004.
Mbewe E et al. Clinical and demographic features of treated first-episode psychotic disorders: a Zambian study. Schizophr Res. 86(1-3):202-7, 2006.
McArthur JC et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS cohort study. Neurology 43(11):2245-2252.
McArthur JC et al. Human immunodeficiency virus-associated dementia: an evolving disease. Journal of NeuroVirology, 2003.
Miller S. Neurological complications of HIV infection. Presented at the Botswana International HIV Conference, Gaborone, 2006.
Nakasujja N et al. Human immunodeficiency virus neurological complications: an overview of the Ugandan experience. J Neurovirol; 11 Suppl 3:26-9, 2005.
Nath A, Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol. 19(4):358-61, 2006.
Navia BA et al. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology;51(1):221-8, 1998.
Olley BO et al. Persistence of psychiatric disorders in a cohort of HIV/AIDS patients in South Africa: a 6-month follow-up study. J Psychosom Res 61(4):479-84, 2006.
Olley BO et al. Post-traumatic stress disorder among recently diagnosed patients with HIV/AIDS in South Africa. AIDS Care;17(5):550-7, 2005.
Perriens JH et al. Neurological complications of HIV-1-seropositive internal medicine inpatients in Kinshasa, Zaire. JAIDS. 2:333-340, 1992.
Price RW. HIV-1 infection of the central nervous system (CNS) and the AIDS dementia complex (ADC): Introduction & some issues for Africa. Presented at Assessment of NeuroAIDS in Africa. Blantyre, Malawi, 2004.
Robertson K et al. Assessment of neuroAIDS in Africa. J Neurovirol; 11 Suppl 1:7-16, 2005.
Robertson KR et al. Highly active antiretroviral therapy improves neurocognitive functioning. JAIDS, 36(1):562-566, 2004.
Sacktor NC et al. The International HIV Dementia Scale. Neurology 60;1:A186-187, 2003.
Sacktor NC et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS;19(13):1367-74, 2005.
Sacktor NC et al. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 67(2):311-4, 2006.
Sacktor NC. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. Journal of NeuroVirology 8(2) Supplement 1, pgs 115 – 121, 2002.
Sacktor NC. Assessment of HIV dementia in Uganda. Results from the Academic Alliance Cohort. Presented at Assessment of NeuroAIDS in Africa, Tanzania, 2006.
Sacktor NC et al. HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of Neurovirology 8(2):136-142, 2002.
Sacktor NC et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56(2):257-260, 2001.
Sevigny JJ et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol. 64(1):97-102, 2007.
Shiu C et al. HIV-1 gp120 as well as alcohol affect blood-brain barrier permeability and stress fiber formation: involvement of reactive oxygen species. Alcohol Clin Exp Res.;31(1):130-7, 2007.
Stern Y et al. Factors associated with incident human immunodeficiency virus-dementia. Archives of Neurology 58(3):473-479, 2001.
Taore M et al. Neuro AIDS in Mali: Present and future research activities. Presented at Assessment of NeuroAIDS in Africa, Tanzania, 2006.
Tozzi V et al. Neurocognitive impairment and survival in HIV-positive patients treated with HAART: results from an urban observational cohort. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 507, 2004.
Valcour VG et al. Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS 18: 379-386, 2004a.
Valcour V et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 63: 822-827, 2004b.
Wang GJ et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127(11): 2452-8, 2004.
Wong MH et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 68:350-355, 2007.
Wilt SG et al. In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 Encephalopathy. Ann Neurol 37(3):381-394, 1995.
Zink MC et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA ;293(16):2003-11, 2005.
Zink MC. Impact of minocycline on SIV CNS and PNS Disease. Presented at Assessment of NeuroAIDS in Africa, Tanzania, 2006.
The World Federation of Neurology: http://www.wfneurology.org/
Also presentations from the Assessment of NeuroAIDS conference are available online at: http://nerve.neurology.unc.edu/ana/archive.htm].